Recombinant CCN Domain Proteins and Fusion Proteins
Summary
USPTO granted Patent US12606602B2 to Oslo University Hospital HF covering recombinant proteins having CCN family thrombospondin type 1 repeat homology domains and fusion proteins combined with fusion partners and linker regions. The patent contains 18 claims and includes novel protease resistant Fc-fragments with applications in oncology.
“The present invention relates to recombinant proteins having an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins and the use thereof.”
What changed
USPTO granted Patent US12606602B2 to Oslo University Hospital HF covering recombinant proteins with CCN family thrombospondin type 1 repeat homology domains, fusion proteins combining these domains with fusion partners and linker regions, and novel protease resistant Fc-fragments. The patent contains 18 claims.
Pharmaceutical and biotechnology companies developing CCN protein therapeutics should review freedom-to-operate implications. The issued patent may affect product development strategies involving thrombospondin type 1 repeat domain technology. No immediate compliance obligations arise from a patent grant itself — this is a property rights event rather than a regulatory requirement.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Recombinant CCN domain proteins and fusion proteins
Grant US12606602B2 Kind: B2 Apr 21, 2026
Assignee
OSLO UNIVERSITETSSYKEHUS HF
Inventors
Håvard Attramadal, Ole Jørgen Kaasbøll
Abstract
The present invention relates to recombinant proteins having an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins and the use thereof. Furthermore, the present invention relates to fusion proteins comprising an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins combined with a fusion partner and optionally a linker region. Also, novel protease resistant Fc-fragments are disclosed herein.
CPC Classifications
A61K 38/00 C07K 2319/31 A61P 35/00 C12N 15/62
Filing Date
2020-03-20
Application No.
17440576
Claims
18
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.